ClinicalTrials.gg
RecruitingNCT06514846Updated Jul 30, 2024

Utilizing the Michigan Neuropathy Screening Instrument for Early Detection of Diabetic Neuropathy

An observational study in Diabetic Polyneuropathy, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 33 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-07-30.

Sponsored by Sohag University · Observational

How we know · 2 judgments

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
100
Ages
33 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 31 studies in Diabetic Neuropathies with a site in Egypt — 9 open to participants now, 9 under way, none of them phase 3. Diabetic Neuropathies · Egypt.

Started
2023
with 5 others
Observational
9 of 31
4 open now
Registered
22nd of 31
by date

Among the 31 studies in Diabetic Neuropathies with a site in Egypt, this one is one of 6 that started in 2023, is one of 9 observational ones, and was the 22nd registered.

Diabetic Neuropathies

539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.

Browse Diabetic Neuropathies studies →

Open to participants now

9 of the 31 studies in Diabetic Neuropathies with a site in Egypt are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 33 Years to 65 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Diabetic Neuropathies with a site in Egypt, or all of them as a file.
02

Study summary

The study aims to Compare the diagnostic accuracy of the Michigan Neuropathy Screening Instrument (MNSI) (using MNS questionnaire, ,Inspection, vibratory sensation, Ankle reflexes Exam, 10 g monofilament needle examination), routine NCS, and the U/S of the median, posterior tibial, and sural nerves in identifying diabetic peripheral neuropathy in patients recently diagnosed with type 2 diabetes.

03

Conditions studied

  • Diabetic Polyneuropathy

Browse trials for

04

Who can participate

Ages eligible
33 Years to 65 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

Place of study: Participants will be recruited from the diabetes clinic, Sohag university hospital.

  • Type of the study: Cross-Sectional Comparative study.
  • Patients:

v Study group: participants of the study will meet the following criteria:

Ø Inclusion criteria:

ü Age: 30-55 y

ü Type of diabetes: Type 2

ü Duration of diabetes: Within 1Year of diagnosis of Type 2 diabetes mellitus according to World Health Organization 1999 criteria

ü Gender: Both males \& females

Ø Exclusion criteria:

Patients who had known conditions that could present with neuropathy such as hereditary sensory neuropathy, vitamin B12 or folate deficiency, paraneoplastic conditions, autoimmune diseases, uremia, hypothyroidism, and ethanol abuse.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ü Age: 30-55 y

ü Type of diabetes: Type 2

ü Duration of diabetes: Within 1Year of diagnosis of Type 2 diabetes mellitus according to World Health Organization 1999 criteria

Exclusion criteria

Exclusion Criteria:

  • Patients who had known conditions that could present with neuropathy such as hereditary sensory neuropathy, vitamin B12 or folate deficiency, paraneoplastic conditions, diseases, uremia, hypothyroidism, and ethanol abuse.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients Group

    Study Population: Place of study: Participants will be recruited from the diabetes clinic, Sohag university hospital. Type of the study: Cross-Sectional Comparative study. Patients: v Study group: participants of the study will meet the following criteria: Ø Inclusion criteria: ü Age: 30-55 y ü Type of diabetes: Type 2 ü Duration of diabetes: Within 1 Year of diagnosis of Type 2 diabetes mellitus according to World Health Organization 1999 criteria ü Gender: Both males \& females Ø Exclusion criteria: Patients who had known conditions that could present with neuropathy such as hereditary sensory neuropathy, vitamin B12 or folate deficiency, paraneoplastic conditions, autoimmune diseases, uremia, hypothyroidism, and ethanol abuse.

06

What researchers measure

Primary outcomes

  1. Early detection of Diabetic Neuropathy

    Utilizing the Michigan Neuropathy Screening Instrument, routine nerve conduction study, and nerve ultrasound for early detection of Diabetic Neuropathy

    Time frame: Searching in patients diagnosed within 1 year or less

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2023 (actual). Primary completion is estimated for Jun 2025, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2024
First posted
Jul 23, 2024
StartActual
Jun 1, 2023
Primary completionEst.
Jun 1, 2025
CompletionEst.
Jun 1, 2025
Last update
Jul 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06514846
Lead sponsor
Sohag University
Responsible party
Reda Khalafallah Khalil (Principal investigator, Sohag University) — Principal investigator
First posted
Jul 23, 2024
Start date
Jun 1, 2023
Primary completion
Jun 1, 2025 (estimated)
Completion
Jun 1, 2025 (estimated)
Last update
Jul 30, 2024

Study contacts

Reda Khalaf Allah Khalil, Resident
Contact
redakhalaf@med.sohag.edu.eg
0102 006 5913

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion